Things to Know Before Applying for IPO of Om Megashree Pharmaceuticals; IPO Opens Today For Foreign Nepalese Immigrants
Mon, Feb 3, 2025 7:39 AM on IPO/FPO News, Latest,
Company Profile:
Om Megashree Pharmaceuticals Limited, established on June 12, 2016, is a public limited company in Nepal, promoted by a group of institutional and individual investors. The company manufactures pharmaceutical products at its Chitwan-based plant and began partial operations on February 19, 2024.
About the Issue:
Om Megashree Pharmaceuticals Limited has issued its IPO to Nepalese citizens working abroad from the 21st Magh to the 5th Falgun, 2081. Note that the issue will not be extended from the early closing date for Nepalese citizens working abroad.
The company's issued capital is Rs. 60 Crores, of which 30%, i.e., 18,00,000 unit shares worth Rs. 18 Crores will be issued later for the general public. Of this public issue, 10% of the shares, totaling 1,80,000 unit shares, have been allocated for Nepalese citizens working abroad, the issue of which opened today.
Out of the total 18,00,000 units, 90,000 (i.e. 5% of 18,00,000) have been set aside for mutual funds and 54,000 (i.e. 3% of 18,00,000) units have been set aside for the employees of the company. The remaining 14,76,000 units are for the general public.
For Nepalese citizens working abroad, the minimum application quantity to be applied is 10 units and the maximum quantity is 10,000 units.
Prabhu Capital Limited has been appointed as the issue manager.
|
Om Megashree Pharmaceuticals Limited |
|
|
|
|
Particulars |
Percentage |
Units |
Amount |
|
Total Capital |
100% |
60,00,000 |
60,00,00,000 |
|
Total Issue to Public (IPO) |
30% |
18,00,000 |
18,00,00,000 |
|
Nepalese Employed Abroad |
10% of IPO Units |
1,80,000 |
1,80,00,000 |
|
Employees |
3% of IPO Units |
54,000 |
54,00,000 |
|
Mutual Fund |
5% of IPO Units |
90,000 |
90,00,000 |
|
General Public |
82% of IPO Units |
14,76,000 |
14,76,00,000 |
|
Issue Manager |
Prabhu Capital Limited |
|
|
|
Issue Open Date |
21st Magh |
|
|
|
Issue Closing Date (earliest) |
5th Falgun |
|
|
|
Minimum Application (For Nepalese Employed Abroad) |
10 |
|
|
|
Maximum Application (For Nepalese Employed Abroad) |
10,000 |
|
|
Capital Structure:
|
Authorized Capital |
60,00,00,000 |
|
Issued Capital |
60,00,00,000 |
|
Current Paid-Up Capital |
42,00,00,000 |
|
Capital after IPO Issuance |
18,00,00,000 |
Shareholding Structures
|
|
Number of shares |
Amount |
Percentage |
Remarks |
|
Promoters |
42,00,000 |
42,00,00,000 |
70% |
Already issued |
|
General Public |
18,00,000 |
18,00,00,000 |
30% |
To be issued |
|
Total |
60,00,000 |
60,00,00,000 |
100% |
|
Board of Directors
|
S.N. |
Name |
Position |
|
1. |
Mr. Arjun Kumar Shrestha |
Chairman |
|
2. |
Mr. Kamal Panthi |
Founding Director |
|
3. |
Mr. Arjun Prasad Kafle |
Founding Director |
|
4. |
Mr. Rabindra Raj Shrestha |
Founding Director |
|
5. |
Mr. Netra Nath Poudel |
Executive Director |
|
6. |
Mr. Sita Ram Joshi |
Marketing Director |
|
7. |
Mrs. Jeni Thapa |
Director |
Financial Highlights:
|
|
Financial Highlights |
|||||
|
Particulars |
Actual |
Estimated |
||||
|
2078/079 |
2079/080 |
2080/081 |
2081/082 |
2082/083 |
2083/084 |
|
|
Total Paid-Up Capital ('000) |
2,00,000 |
2,00,000 |
4,20,000 |
6,00,000 |
6,00,000 |
6,00,000 |
|
Reserve & Surplus ('000) |
61,717.286 |
62,249.422 |
62,423.583 |
62,682.24 |
62,987.772 |
63,312.869 |
|
Net Profit ('000) |
(6,078.347) |
(10,094.703) |
13,872.179 |
34,386.69 |
58,754.514 |
84,623.439 |
|
Earnings per share (Rs.) |
-3.04 |
-5.05 |
3.3 |
5.73 |
9.79 |
14.1 |
|
Net worth per share (Rs.) |
108.85 |
104.07 |
105.03 |
108.55 |
118.28 |
123.92 |
|
Return on Equity (%) |
-2.43% |
-2.82% |
3.14% |
5.28% |
8.28% |
11.38% |
CARE Ratings:
CARE Ratings Nepal Limited (CRNL) has reaffirmed the ‘CARE-NP BB- (Is)’ rating for Om Megashree Pharmaceuticals Limited (OMPL), indicating moderate default risk for timely financial obligations. Additionally, CRNL has reaffirmed the ‘CARE-NP BB-’ rating for OMPL’s long-term bank facilities and the ‘CARE-NP A4’ rating for its short-term bank facilities.
Key Rating Strengths:
Experienced directors and promoters with prior experience in the pharma industry
Steady demand outlook for pharmaceutical products
Key Rating Weakness:
- Operations stabilization risk and residual implementation risk associated with its ongoing capex
- Working capital-intensive nature of business
- Competition from existing players
- Exposure to volatile interest rate
